Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Benzamidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 known ✓ | P09874 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | PRSS1 | P07477 | 5/20 | 0.94 |
| ▸ | PRSS3 | P35030 | 5/20 | 0.94 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.94 |
| ▸ | C1S | P09871 | 2/20 | 0.94 |
| ▸ | RECQL | P46063 | 2/20 | 0.94 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.94 |
| ▸ | F2 | P00734 | 4/20 | 0.94 |
| ▸ | F10 | P00742 | 1/20 | 0.94 |
| ▸ | F12 | P00748 | 1/20 | 0.94 |
| ▸ | F7 | P08709 | 1/20 | 0.94 |
| ▸ | F3 | P13726 | 1/20 | 0.94 |
| ▸ | PKM | P14618 | 1/20 | 0.94 |
| ▸ | WDR5 | P61964 | 1/20 | 0.68 |
| ▸ | APEX1 | P27695 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | PLG | P00747 | 1/20 | 0.56 |
| ▸ | PLAU | P00749 | 2/20 | 0.55 |
| ▸ | MASP2 | O00187 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzamidine SCHEMBL29191424 | 1.00 | BLM (1.00) | BLMPRSS1PRSS3PRSS2C1S | |
| Benzamidine SCHEMBL23235801 | 1.00 | BLM (1.00) | BLMPRSS1PRSS3PRSS2C1S | |
| Benzamidine SCHEMBL27303891 | 1.00 | BLM (1.00) | BLMPRSS1PRSS3PRSS2C1S | |
| Benzamidine SCHEMBL61379 | 1.00 | BLM (1.00) | BLMPRSS1PRSS3PRSS2C1S | |
| Benzamidine SCHEMBL29191425 | 0.97 | BLM (0.94) | BLMPRSS1PRSS3PRSS2C1S | |
| Benzamidine SCHEMBL596593 | 0.97 | PRSS1 (1.00) | BLMPRSS1PRSS3PRSS2C1S | |
| Benzamidine SCHEMBL9040332 | 0.97 | PRSS1 (1.00) | BLMPRSS1PRSS3PRSS2C1S | |
| Benzamidine SCHEMBL28224057 | 0.97 | BLM (0.94) | BLMPRSS1PRSS3PRSS2C1S | |
| Benzamidine SCHEMBL28147189 | 0.97 | BLM (0.94) | BLMPRSS1PRSS3PRSS2C1S | |
| SCHEMBL18557033 | 0.97 | F2 (1.00) | BLMPRSS1PRSS3PRSS2C1S |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1190395-A | Substituted (sulfonic, sulfinic, sulfonamido or sulfonamido) N- [ aminoiminomethyl) phenylalkyl ] -azaheterocyclic amide compounds | RHONE POULENC RORER PHARMA (US) | 1998-08-12 | — | — | CN | claimed |
| US-20250057974-A1 | METHOD FOR CHANGING HYDROGEL VOLUME AND HYDROGEL | TOPPAN HOLDINGS INC. (JP) | 2025-02-20 | — | — | US | disclosed |
| WO-2023127503-A1 | METHOD FOR CHANGING HYDROGEL VOLUME AND HYDROGEL | 凸版印刷株式会社 | 2023-07-06 | — | — | WO | disclosed |
| CN-114845708-A | Compounds for treating bacterial infections and enhancing antibiotics | 乔治亚州大学研究基金会 | 2022-08-02 | — | — | CN | disclosed |
| CN-111957073-B | Affinity chromatography filler for purifying urokinase, preparation method and application | 武汉人福药业有限责任公司 | 2021-12-24 | — | — | CN | disclosed |
| CN-112566631-A | Amidines and amidine analogs for the treatment of bacterial infections and potentiation of antibiotics | 乔治亚州大学研究基金会 | 2021-03-26 | — | — | CN | disclosed |
| CN-111957073-A | Affinity chromatography filler for purifying urokinase, preparation method and application | 武汉人福药业有限责任公司 | 2020-11-20 | — | — | CN | disclosed |
| CN-109836412-A | A kind of preparation method of dabigatran etexilate methanesulfonate | 辽宁博美医药科技有限公司 | 2019-06-04 | — | — | CN | disclosed |
| CN-103193717-B | M-phenyl bipyrimidine compound, and synthesis method and application thereof | 南京工业大学 | 2017-01-25 | — | — | CN | disclosed |
| CN-101801962-A | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases | ASTRAZENECA AB | 2010-08-11 | — | — | CN | disclosed |
| US-5646281-A | FOR USE IN THE DIAGNOSIS AND TREATMENT OF SCHIZOPHRENIA, DEPRESSION AND PARKINSON*S DISEASE | NEUROGEN CORPORATION (US) | 1997-07-08 | — | — | US | disclosed |
| US-5633377-A | DIAGNOSIS, THERAPY OF SCHIZOPHRENIA, DEPRESSION, PARKINSON'SDISEASE | NEUROGEN CORPORATION (US) | 1997-05-27 | — | — | US | disclosed |
| WO-1997014686-A1 | PHARMACEUTICALLY ACTIVE QUINAZOLINE COMPOUNDS | ASTRA PHARMACEUTICALS LIMITED (GB) | 1997-04-24 | — | — | WO | disclosed |
| WO-1996016040-A1 | CERTAIN 4-AMINOMETHYL-2-SUBSTITUTED IMIDAZOLE DERIVATIVES AND 2-AMINOMETHYL-4-SUBSTITUTED IMIDAZOLE DERIVATIVES; NEW CLASSES OF DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1996-05-30 | — | — | WO | disclosed |
| EP-0713483-A1 | AMIDINE DERIVATIVES WITH NITRIC OXIDE SYNTHETASE ACTIVITIES | Astra Aktiebolag (SE) | 1996-05-29 | — | — | EP | disclosed |
| US-4596818-A | Antidiarrhea agents | BEECHAM GROUP P.L.C. (GB) | 1986-06-24 | — | — | US | disclosed |
| EP-0043159-B1 | POROUS INORGANIC SUPPORT MATERIAL COATED WITH AN ORGANIC STATIONARY PHASE, FOR USE IN CHROMATOGRAPHY, AND PROCESS FOR ITS PREPARATION | AKZO N.V. (NL) | 1985-09-04 | — | — | EP | disclosed |
| EP-0117102-A1 | Amidines | BEECHAM GROUP PLC (GB) | 1984-08-29 | — | — | EP | disclosed |
| US-4415631-A | SILANIZED PARTICLES BONDED TO COPOLYMERIZED VINYL MONOMER CONTAINING AMIDE GROUPS | AKZO (NL) | 1983-11-15 | — | — | US | disclosed |
| EP-0043159-A1 | Porous inorganic support material coated with an organic stationary phase, for use in chromatography, and process for its preparation | AKZO N.V. (NL) | 1982-01-06 | — | — | EP | disclosed |